Image

Speech Production Enhancement Using Augmentative Communication for Kids

Speech Production Enhancement Using Augmentative Communication for Kids

Recruiting
7-17 years
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial is to learn if speech supplementation can improve speech intelligibility in children ages 7 to 17 years with cerebral palsy. The main questions it aims to answer are:

  • To what extent can speech supplementation improve intelligibility in children with CP compared with habitual speech produced without speech supplementation?
  • How much intelligibility change is necessary for meaningful improvement when children use speech supplementation strategies?

Participants will:

  • complete speech and language assessments
  • complete a speech pre-test using habitual speech
  • learn a speech supplementation strategy with training from a speech-language pathologist
  • complete a speech post-test using the speech supplementation strategy
  • complete a speech repetition task where specific words are emphasized (emphatic stress)
  • use the previously learned speech supplementation strategy + emphasis on specific words while producing a set of sentences

Description

This study uses a pre-/post- test design to test the effects of a one-session intervention to improve speech intelligibility in 100 children with cerebral palsy and dysarthria. The intervention involves the augmentative and alternative communication (AAC) strategy known as speech supplementation. Specifically, children will learn how to simultaneously speak and point to the first letter of each word on a communication board, or to speak and point to a topical picture on a communication board. The strategy serves to provide listeners with context cues for spoken words, and it also serves to impact temporo-acoustic features of speech by reducing rate of speech and making word boundaries clear.

In this study, children will first participate in a set of baseline assessment measures, which will include the production of a corpus of 60 sentences (referred to as "habitual speech"). Then, children will learn to use the speech supplementation strategy through one-on-one clinician modeling, teaching, and practice. When children have mastered the strategy on a set of practice sentences, they will complete a post-test in which they produce the same set of elicited sentences a second time using speech supplementation.

Pre-test and post-test speech samples will then be played to two groups of listeners. One group will orthographically transcribe the words produced by children in both conditions (habitual and supplemented). Listener transcriptions in each condition will be scored as correct or incorrect based on whether they matched the intended word. Average percent of words identified correctly will be obtained from 2 listener for each child and each speaking condition as measures of speech intelligibility. The difference between habitual speech (pre-test) and supplemented speech (post-test) will be examined to quantify the effects of the speech supplementation on intelligibility.

The second set of listeners will hear the same speech samples as the first set (habitual speech and supplemented speech), but they will make ratings of whether one of the conditions seems more understandable than the other, and if so, they will rate how much better using a 7-point Likert scale.

These two sets of data from listeners will enable us to measure the minimum detectable difference in speech intelligibility and then the minimal clinically important difference based on listener ratings. Together these measures will enable us to determine how much change in intelligibility is necessary in order for clinically meaningful improvement. The hypotheses are as follows:

  1. speech supplementation will result in increased speech intelligibility relative to habitual speech.
  2. the minimal clinically important difference in intelligibility scores to consider the speech supplementation strategy "successful" will vary depending on child severity, with more severely speech impaired children requiring a larger improvement to achieve a clinically meaningful change.

Eligibility

Inclusion Criteria:

  • Medical diagnosis of cerebral palsy, or a similar, related condition that affects early motor development and presents as a chronic motor disability
  • Age between 7 and 17 years
  • Clinical dysarthria with speech intelligibility between 10-85 percent
  • Able to produce connected speech in English, with a minimum utterance length of 3 words
  • Able to use hands to point to items on a communication board
  • Cognitive/language skills that enable basic picture identification on a communication board
  • Pass pure tone hearing screening

Exclusion Criteria:

  • Failure to meet all inclusion criteria.
  • Vision impairment that precludes being able to see items on a communication board.
  • Not suitable for participation due to other reasons at the discretion of the investigators.

Study details
    Cerebral Palsy (CP)
    Intelligibility
    Speech
    Augmentative and Alternative Communication

NCT07173049

University of Wisconsin, Madison

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.